Tuberculous meningitis (TBM) remains a major cause of death and disability in tuberculosis-endemic areas, especially in young children and immunocompromised adults. Research aimed at improving outcomes is hampered by poor standardization, which limits study comparison and the generalizability of results. We propose standardized methods for the conduct of TBM clinical research that were drafted at an international tuberculous meningitis research meeting organized by the Oxford University Clinical Research Unit in Vietnam. We propose a core dataset including demographic and clinical information to be collected at study enrollment, important aspects related to patient management and monitoring, and standardized reporting of patient outcomes. The criteria proposed for the conduct of observational and intervention TBM studies should improve the quality of future research outputs, can facilitate multicenter studies and meta-analyses of pooled data, and could provide the foundation for a global TBM data repository.
Tuberculous meningitis (TBM) was almost universally fatal until the first antibiotic treatment with streptomycin and isoniazid became available [1] . TBM remains a major cause of disease, disability, and death in tuberculosis-endemic areas, but research aimed at improving outcomes is hampered by difficulties in patient recruitment and heterogeneous research methodology. The development of a consensus TBM case definition for use in TBM research has assisted new diagnostic studies by providing a uniform reference standard [2] . However, variable data collection methods, different disease classification systems, and the absence of standardized outcome assessment continue to limit study comparison and complicate efforts to perform systematic reviews and meta-analyses.
The need to standardize clinical trial endpoints is well recognized for pulmonary and drug-resistant tuberculosis research and is the focus of several international consortia (eg, PreDICT-TB [www. predict-tb.eu], RESIST-TB [www.resisttb.org], and TREAT-TB [www.treattb.org]). Core research methods have been proposed for adults and children with multidrug-resistant tuberculosis [3, 4] . In this context, the Oxford University Clinical Research Unit in Vietnam, together with the University of Cape Town's Clinical Infectious Diseases Research Initiative, organized a meeting of international TBM researchers in Dalat, Vietnam (20-22 May 2015) to assess recent progress and address key challenges in TBM research. Researchers actively engaged in TBM research worldwide were invited with the aim of creating an international consortium that could make recommendations concerning the objectives and methodology of future TBM clinical research.
A TBM research methodological framework was discussed and agreed upon during the meeting by all delegates, broadly defining the key baseline, treatment, and outcome data required in the conduct of TBM research. Thereafter, proposed essential and desirable data were circulated by the lead authors (B. J. M., A. D. H., and G. E. T.) and agreed or adapted by the writing committee (all listed authors) until consensus was found. A statement thereby arose from the meeting, proposing standardized criteria for the conduct and reporting of TBM research and shared data collection templates. We provide an overview of the consensus reached by the consortium, identifying demographic and clinical information to be collected at study enrollment, important aspects related to patient management and monitoring, and standardized reporting of patient outcomes. Specific data points were categorized as either essential or desirable. The essential data points are intended to define minimum criteria for the conduct of both observational and intervention studies, and to identify a core dataset for universal use in future clinical research. Better-harmonized research methods would improve the quality of research outputs and facilitate study comparisons and, in the future, may provide the foundation for a global TBM data repository.
COHORT DESCRIPTION AND METHODS
Adequate cohort description with clarification of the clinical "point of entry" is essential to ensure study reproducibility and to interrogate differences in study outcomes that may be unrelated to the intervention studied. Because treatment outcomes and diagnostic test performance may vary according to the severity of disease, age, immune status, and patient management, the study population must be well characterized in terms of setting, inclusion criteria, demographics, human immunodeficiency virus (HIV) infection and immune status, disease classification, and treatment received. Table 1 provides a summary of essential and desirable baseline information to be collected at study enrollment. Essential data points include information required by the previously published uniform TBM research case definition (Table 2) [2], which should be applied to ensure adequate diagnostic workup and to characterize the study cohort in a standardized fashion. For diagnostic studies, it is important to ensure that control subjects represent a credible clinical entry point for TBM diagnostic evaluation, to assess "real-life" diagnostic accuracy.
INFORMATION TO COLLECT AT ENROLLMENT

Disease Severity and Phenotype
Given the diversity of clinical presentation and disease severity, it is important to grade TBM severity in a pragmatic and standardized fashion. As a minimum, HIV status (preferably with CD4 count and World Health Organization [WHO] clinical disease staging) must be recorded and the modified British Medical Research Council (BMRC) TBM grade should be ascertained in all studied patients before the start of treatment. BMRC investigators [1] first graded TBM patients as "early" (no clinical signs of meningitis or focal neurology and fully conscious); "medium" (patient's condition falling between early and advanced); and "advanced" (extremely ill, in deep coma). With the introduction of the Glasgow Coma Scale (GCS) in 1974 [5] , this was modified as grade I (GCS 15; no focal neurological signs), grade II (GCS 11-14, or 15 with focal neurological signs), and grade III (GCS ≤10) disease [6] . Numerous studies across all age groups have shown that the modified BMRC grade is a strong independent predictor of outcome [6] [7] [8] [9] [10] . TBM patients with grade I disease are often underrepresented in studies, as their nonspecific symptoms may not trigger a lumbar puncture, which usually provides the entry point for TBM studies. Subdivision of grade II disease has been proposed [11] , as have other prognostic systems based on weighted scoring of mental status, seizures, cranial nerve palsies, motor deficit, and tone [12] , but these have not been validated. Because level of consciousness is influenced by rapidly reversible raised intracranial pressure and electrolyte disturbances, it is important to repeat the BMRC disease severity grading 7 days after TBM treatment initiation. This provides a useful reassessment of disease severity that may be better associated with long-term outcome than a single baseline assessment.
Baseline Investigations
Essential and desired study investigations, to be performed at enrollment, are summarized in Table 1 . Cerebrospinal fluid (CSF) sampling and analysis are essential to assist diagnostic workup and cohort description and to define prognosis. Low CSF white blood cell count, low glucose, and high lactate have been associated with death in studies from Vietnam [13] . In HIV-coinfected patients, baseline CSF neutrophil count and culture positivity for Mycobacterium tuberculosis are predictive of TBM immune reconstitution inflammatory syndrome (IRIS) [14] . Cryptococcal meningitis and TBM have similar presenting features and CSF cryptococcal antigen tests should be performed, especially in those with advanced HIV infection (peripheral CD4 + count <100 cells/µL), in whom both diseases are common. Peripheral blood findings have limited diagnostic or prognostic value, but it is important to document anemia, determine baseline renal and liver function tests for drug toxicity monitoring, and assess HIV and immune status. Hyponatremia has been linked to a worse outcome [15] , while in HIV-1-coinfected patients lower blood hematocrit [13] and low CD4 + T-cell count [16, 17] have been associated with death.
Brain computed tomography (CT) with or without contrast and magnetic resonance imaging (MRI) characterize the pathological processes underlying the clinical presentation, disease course, and long-term consequences of TBM. Baseline brain imaging is recommended for all patients, although this may not be available in all settings [18] . Classic imaging findings include basal meningeal enhancement, hydrocephalus, tuberculomas, and cerebral infarction [19] . MRI is more sensitive in detecting early ischemia and brainstem lesions [20] . TBM-related infarcts are most commonly located in the territories of the proximal middle cerebral artery and the medial lenticulostriate and thalamoperforating vessels [21, 22] . Brain imaging provides a window on the pathophysiology of TBM, and standardized documentation of these complications and their response to treatment could improve management and may suggest new therapeutic approaches. Diagnostic yield is influenced by both the type and quality of specimens collected; therefore careful description of specimen collection methods and test procedures are important. Microbiological yield is affected by CSF volume, sample transport delays, and processing techniques [23] . The CSF sample volume used for each mycobacterial diagnostic test should be reported. In addition, adequate quality assurance of all research laboratories is essential to ensure test reliability. 
MANAGEMENT AND MONITORING
Ensuring minimal standards of ancillary care and patient monitoring is essential for ethical reasons and for reporting purposes, as differences in local management practices are important confounders when assessing outcomes. Management and monitoring protocols should be adequately described, including (1) antituberculosis drug treatment; (2) adjunctive anti-inflammatory therapy; (3) management of hydrocephalus; and (4) other supportive care ( Table 3, Figure 1 ).
Antituberculosis Drug Treatment
As summarized in Table 3 , it is essential to document the dose, route of administration, and duration of all antituberculosis drugs used in TBM treatment. Antituberculosis drug-related adverse events are more important in the treatment of TBM than other forms of tuberculosis because treatment interruptions have been independently associated with death [24] . Druginduced liver injury (DILI) is the commonest adverse event and should be documented alongside changes in antituberculosis drug regimen. Outstanding questions remain concerning optimal management when DILI occurs, and harmonized data collection would allow analyses to address these.
When performing antituberculosis drug treatment trials, it is important to document drug quality as this can be highly variable. WHO-prequalified drugs have been rigorously evaluated and meet strict quality criteria (a list of prequalified drugs is available at http://apps.who.int/prequal/query/ProductRegistry. aspx). For other drugs, pharmaceutical companies should provide "certificates of analysis" and data on bioequivalence.
Pharmacokinetic/Pharmacodynamic Substudies
Pharmacokinetic/pharmacodynamic (PK/PD) substudies can help to explain trial findings and provide important dosing information for future studies. Evaluation of individual exposures achieved provides insight into predictors of drug exposure and enables concentration-response relationships (PK/PD analysis) to be established [25] [26] [27] ; the latter may reveal exposure thresholds predictive of good treatment outcome or drug toxicity [26, 28, 29] . Pharmacokinetic analysis should ideally include both plasma and CSF measurements, although CSF concentrations may not reflect the brain tissue concentration of highly lipophilic drugs [30, 31] . Pharmacokinetic studies often take place at "steady state, " when the processes of accumulation or induction are complete (in rifampicin this can take up to 10 days), but in TBM we suggest measuring exposures during the critical first days of treatment when mortality is highest [27] . CSF sampling after weeks of treatment may yield different results, as CSF drug penetration may reduce as meningeal inflammation lessens.
The standard method to assess CSF penetration is the CSF to plasma ratio for total drug exposure (area under the concentration-time curve [AUC]) during the dosing interval, which requires multiple plasma and CSF samples [25] . Alternatively, a CSF to plasma concentration ratio can be established by a single point measurement, but this is time dependent as the ratio is often variable over the dosing interval [31] . Although single time point CSF to plasma ratios should be interpreted with caution, pharmacokinetic modeling may approximate the CSF to plasma AUC ratio despite limited sampling, if such sampling takes place at multiple time points. It is important that CSF to plasma concentration ratios should be based upon estimated protein-unbound ("free") exposure measures. In plasma, only the protein-unbound fraction is active and able to penetrate Probable TBM: total score of ≥12 when neuroimaging available or total score of ≥10 when neuroimaging unavailable. At least 2 points should either come from CSF or cerebral imaging criteria.
Possible TBM: total score of 6-11 when neuroimaging available, or total score of 6-9 when neuroimaging unavailable.
Abbreviations: AFB, acid-fast bacilli; CNS, central nervous system; CSF, cerebrospinal fluid; CT, computed tomography; IGRA, interferon-γ release assay; MRI, magnetic resonance imaging; NAAT, nucleic acid amplification test; TB, tuberculosis; TBM, tuberculous meningitis; TST, tuberculin skin test; US, ultrasound.
into the CSF. If a drug with high protein binding in plasma has excellent CSF penetration, a CSF to plasma ratio based on protein-unbound concentrations would be close to unity. In contrast, a ratio based on total (bound + unbound) concentrations would incorrectly suggest poor penetration [31] , as is the case with rifampicin. Therefore, a correction for protein binding of plasma concentrations should always be made [25, 26] . Pharmacokinetic sampling can be "intensive" or "sparse," or ideally a mixture of both to assist accurate modeling. Analytical methods used to determine drug concentrations should have appropriate intralaboratory (internal) assessment of accuracy, precision, and other validation measures. Participation in an interlaboratory (external) proficiency testing program is recommended [32] . Of note, CSF drug concentrations cannot be measured using plasma assays without careful validation.
Adjunctive Anti-inflammatory Therapy
TBM studies should describe the type, dose, route of administration, and duration of anti-inflammatory therapy used (Table 3) . Adjunctive corticosteroids are currently recommended for all HIV-uninfected TBM patients during the first 6-8 weeks of treatment [9] ; they are also used in HIV-infected patients, although the evidence of benefit is much less clear.
Corticosteroids are also often used for the management of tuberculomas and IRIS in HIV-infected patients, although the evidence base is weak. Some patients who do not respond to corticosteroids may benefit from other agents, such as thalidomide or anti-tumor necrosis factor-α biologic agents [33] [34] [35] [36] . Two small studies also suggest that aspirin may reduce cerebral infarcts [37, 38] , but this has not been confirmed in larger-scale studies.
Management of Hydrocephalus
As a minimum, the presence of hydrocephalus assessed by brain CT or MRI should be documented at the start of treatment. An assessment of whether the hydrocephalus is communicating or noncommunicating is desirable, and the management (medical or surgical) should be documented (Table 3) . Raised intracranial pressure, largely due to hydrocephalus, is a common problem in patients with TBM [10, 39] . If untreated, hydrocephalus can exacerbate the cerebral ischemia caused by perfusion-limiting vasculitis, which is a key feature of TBM. Untreated hydrocephalus is independently associated with death [40, 41] . Whether the hydrocephalus is communicating or noncommunicating [10, 42] has important management implications. At present, the only way to reliably differentiate communicating from noncommunicating If the diagnosis of TBM is uncertain, it is recommended to repeat CSF analysis 3-7 days after the start of treatment. Otherwise, CSF after 30 and 60 days of treatment can help to assess treatment response and likelihood of drug resistance. c As a minimum, blood tests should be performed at diagnosis, weekly during the first month, and monthly during the first 6 months.
hydrocephalus is with an air encephalogram or using contrast ventriculography [43, 44] . Performing an air encephalogram does not require any special resources and can be performed when collecting a CSF sample. Ventricular shunting is usually indicated for noncommunicating hydrocephalus, while a combination of diuretics (acetazolamide and furosemide) may treat communicating hydrocephalus [45] ; the value of this approach requires further confirmation in adults.
General Supportive Care
The provision of optimal supportive care in patients with TBM is rarely reported and often neglected and is therefore highlighted here. Hyponatremia occurs in a high percentage of TBM patients, is associated with poorer outcome [10] , and should be documented (Table 3) . Hyponatremia may result from inappropriate antidiuretic hormone secretion or cerebral salt wasting or may represent an appropriate compensatory response to maintain cerebral perfusion. Plasma sodium concentrations should be recorded at baseline and through the early phase of hospital treatment. In critically ill patients, changes in cerebral perfusion and oxygenation are highly dynamic, but can be captured through continuous intracranial monitoring. This is invasive and only possible during intensive care admission in settings where such facilities exist. Transcranial Doppler [46] and near-infrared spectroscopy provide less-invasive alternatives, but these methods require more rigorous validation and
have not yet demonstrated clinical utility. Simple measures to reduce cerebral ischemia and brain cell metabolic stress include maintaining adequate blood pressure and glucose levels, providing supplemental oxygen, and controlling fever [47] . These parameters should be recorded in all critically ill patients (Table 3) .
OUTCOME MEASURES
The inconsistent reporting of outcome measures limits critical study evaluation and comparison. TBM is associated with high mortality; therefore, death is an essential outcome measure. The time of death in relation to the start of antituberculosis treatment should also be documented, and we recommend reporting to at least 12 months from antituberculosis treatment initiation. Cause of death is notoriously difficult to determine without formal postmortem examination, but deaths directly attributable to TBM are more likely to occur in the first 3 months of treatment; later deaths may be caused by secondary infections, for example, especially in those left with severe neurological disability. An assessment by the attending physician as to the likely cause of death (TBM attributable/not attributable) is desirable but not essential, given the inherent limitations of this approach. The reporting of functional outcomes are also essential, but different measures are used [9] , and detailed neurocognitive outcomes are rarely assessed [48] . Given the importance of neurodisability and comparable outcome measurement, we recommend that the Modified Rankin Score should be recorded 12 months from antituberculosis treatment initiation in all adults and in children. The score (detailed in the Supplementary Appendix) assesses whether or not the subject can live independently of others. We also recommend recording the Pediatric Version of the Glasgow Outcome Scale-Extended (GOS-E peds) in children (Table 4) ; however, this scale, created for children following neurotrauma, needs further validation in childhood TBM.
TBM causes significant long-term neurocognitive impairment in children [10, 49] and adults [7] , and detailed neurocognitive and psychiatric outcomes should be reported where possible. The Griffiths Mental Developmental Scales or the Pediatric Cerebral Performance Category Scale provide assessment on age-appropriate neurocognitive and developmental outcomes. It is important that children are compared to agematched controls from the same socioeconomic background, given major environmental influences on early cognitive development.
Paradoxical Reactions
Clinical deterioration after the start of antituberculosis treatment-commonly called paradoxical reactions and associated with increased intracerebral inflammation-occurs in approximately 30% of HIV-uninfected individuals with TBM [50] and around 50% of those who are HIV infected [14] . Paradoxical reactions are associated with new or worsening intracerebral tuberculomas, hydrocephalus, infarcts, and/or spinal radiculomyelitis. In HIV-infected subjects recently started on antiretroviral therapy, these events may be defined as TBM-IRIS following the International Network for the Study of HIV-Associated IRIS criteria [51] , modified for TBM. All suspected paradoxical reactions and their timing with respect to antituberculosis drug initiation should be recorded (Table 4) . When possible, providers should investigate all suspected paradoxical reactions with brain imaging and document the findings, management given, and outcomes. Alternative causes that should be excluded as far as possible include drug resistance, poor adherence to treatment, drug-related adverse events, and other opportunistic infections. We also recommend that all WHO HIV stage 4 illnesses should be recorded throughout the course of TBM treatment (Table 4) .
PROPOSED CORE DATASET
Participants at the workshop reinforced calls for standardized approaches, including laboratory and clinical assessment procedures and data reporting. All laboratory tests should be guided by detailed standard operating procedures, including sample collection, processing, transport, storage, and laboratory procedures for specific diagnostic tests, including quality assurance measures; relevant standard operating procedures are included in the Supplementary Data. Demographic and clinical data should also be collected in a standardized fashion. The essential elements listed in the tables provide the basis for a core dataset that represents the minimum data to be captured in future TBM studies. A proposed data capture form that includes all the proposed "essential" and "desirable" variables (Tables 1-4) is included in the Supplementary Data.
CONCLUSIONS
Developing standardized approaches represents a critical first step to establish the evidence base required to improve TBM detection and outcome. Poor study comparability due to variable methods, case definitions, and data collection and reporting highlight the inadequacy of current approaches. Wide adoption of the standard methods proposed here should help to move the field forward and ensure that the benefits of technological advances are fully realized. This document should be viewed as a living tool that will be refined as the evidence base and field experience with conducting multicenter TBM studies grow and are critically evaluated at future meetings. Any adverse event, adverse reaction, or unexpected adverse reaction that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or consists of a congenital anomaly or birth defect.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.
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